EUCTR2015-001932-38-NL进行中（未招募）1 期
A randomised, double-blind, placebo-controlled, single-centre phase IIb trial as part of the EU-funded UNISEC project to assess the immunogenicity and safety of different formulations and dosing regimens of FLU-v vaccine administered subcutaneously in healthy adults aged 18-60 years.
PepTcell Limited (trading as SEEK)0 个研究点目标入组 175 人开始时间: 2016年7月20日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 175
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Healthy males or healthy non-pregnant females (as indicated by a negative blood pregnancy test done during the screening visit) between the ages of 18 and 60 years, inclusive;
- •- Women of childbearing potential (not surgically sterile or postmenopausal for greater than or equal to one year) and men must agree to practice appropriate contraception (a combination of barrier and hormonal methods for women and a condom for men) from screening and until at least 30 days (up to Study Day 51 for females) and 90 days (up to Study Day 111 for males), after the last vaccination.
- •- A subject is in good health, as determined by a comprehensive clinical assessment {vital signs (heart rate, blood pressure, oral temperature)}, blood chemistry test (electrolytes, renal/kidney function, liver function, C-reactive
- •protein, complete blood count), medical history, general physical examination, self-reported illness} and the clinical judgment of the investigator;
- •- Able to understand and comply with planned study procedures;
- •- Provides signed informed consent form
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 222
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Has a known allergy to any of the components of the vaccine.
- •- Has a history of severe reaction following immunization.
- •- Persons with immune deficiency/disorder, whether due to genetic defect, immunodeficiency disease, or immunosuppressive therapy.
- •- Women who have a positive pregnancy test during the screening visit or who are breastfeeding.
- •- Has a history of any of the following (reported by subjects):
- •o Acute disseminated encephalomyelitis (ADEM);
- •o Neoplastic disease – current or previous;
- •o Asthma or severe allergic disease;
- •o Bleeding disorders
- •o Chronic Hepatitis B and/or C infection;
- •o Chronic liver disease;
- •o Diabetes mellitus;
- •o Guillain-Barré syndrome;
- •o Rheumatoid arthritis or other autoimmune diseases;
- •o Severe renal disease;
- •o Transplant recipients;
- •o Unstable or progressive neurological disorders.
- •- Receipt of medicines/treatments that may affect evaluation of immunogenicity such as:
- •o Oral or parenteral steroids, high-dose inhaled steroids (greater than 800 micrograms/day of beclomethasone dipropionate or equivalent) or other immunosuppressive or cytotoxic drugs (azathioprine (Imuran), cyclosporine (Neoral, Sandimmune, SangCya); monoclonal antibodies such as basiliximab (Simulect), daclizumab (Zinbryta), infliximab (Remicade), rituximab (MabThera), alemtuzumab (Campath and Lemtrada), omalizumab (Xolair), abatacept (Orencia), adalimumab (Humira and Exemptia) and etanercept (Enbrel)basiliximab (Simulect), daclizumab (Zenapax), and muromonab (Orthoclone OKT3); corticosteroids such as prednisone (Deltasone, Orasone); tacrolimus (Prograf, Advagraf, Protopic); Glatiramer acetate (Copaxone); Mycopehnolate (Cellcept); Sirolimus (Rapamune); (within 6 months of vaccination in this study)
- •o Immunoglobulin or other blood products (within 3 months of vaccination
- •in this study);
- •o An experimental agent (vaccine, drug, biologic, device, blood product, or medication) within 1 month of vaccination in this study, or expects to receive an experimental agent (during the study period).
- •o Influenza antiviral medication (within 4 weeks of vaccination in this study).
- •- Has received any influenza vaccine within 6 months of vaccination in this study
- •- Has influenza-like illness (a sudden onset of symptoms and at least one of the four systemic symptoms-fever or feverishness, malaise, headache, myalgia and at least one of the three respiratory symptoms-cough, sore throat, shortness of breath) or acute respiratory infection (a sudden onset of symptoms and at least one of the four respiratory symptoms-cough, sore throat, shortness of breath, coryza (Rhinitis) and a clinician’s judgement that the illness is due to
- •an infection) within 6 months prior to vaccination in this study. These symptoms must have stopped the subject from carrying out their normal daily activities such as attending work or school for a period of at least 3 days.
- •- Has an acute illness, including an oral temperature greater than 38 degrees Celsius, within 1 week of vaccination.
- •- Has a history of alcohol or drug abuse within the last 2 years deemed unsuitable for inclusion by the investigator.
- •- Any abnormal haematology values and/or serum chemistries judged by the Investigator as clinically significant.
研究者
相似试验
已完成
1 期
Safety, blood levels and effects of AUT00201Phase I study in healthy volunteers of a treatment to improve/or normalize symptoms and deficits in patients with rare neurological disorders associated with reduced Kv3 channel functionISRCTN18263497Autifony Therapeutics (United Kingdom)57
进行中（未招募）
不适用
A trial to compare lomitapide at different doses with placebo with regards to safety, what the drug does, and where the drug goes, in Japanese and Caucasian volunteers who have higher then normal cholesterol levelsPersons with elevated low-density-lipoprotein - cholesterol levels (at least 110 mg/dL).MedDRA version: 14.1Level: LLTClassification code 10024055Term: LDL cholesterol increasedSystem Organ Class: 100000004848EUCTR2012-004220-37-GBAegerion Pharmaceuticals Inc
已完成
不适用
A randomised, double-blind, placebo-controlled, single ascending dose/multiple dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of KBP-042 in healthy adult male volunteers.adult-onset diabetestype 2 diabetes mellitus10018424NL-OMON42391KeyBioscience67
已完成
不适用
A randomised, double-blind, placebo-controlled, single ascending dose, Phase I study to evaluate the safety, tolerability, and pharmacokinetics of PG110 (anti-NGF monoclonal antibody) in patients with pain attributed to osteoarthritis of the kneeosteoarthritisNL-OMON35149Abbott B.V.56
进行中（未招募）
1 期
Study to investigate the safety of VRG50635 in healthy volunteers and patients with motor neuron disease (amyotrophic lateral sclerosis)ISRCTN14792372Verge Genomics93